TY - JOUR
T1 - Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers
AU - Bijsterveld, Nick R.
AU - Vink, Roel
AU - van Aken, Benien E.
AU - Fennema, Hein
AU - Peters, Ron J. G.
AU - Meijers, Joost C. M.
AU - Büller, Harry R.
AU - Levi, Marcel
PY - 2004
Y1 - 2004
N2 - We investigated whether the anticoagulant effect of idraparinux, a selective long-acting factor Xa inhibitor, could be neutralized by recombinant factor VIIa (rFVIIa) in healthy male volunteers. We performed a randomized, placebo-controlled trial, comparing idraparinux [7.5 mg subcutaneous (s.c.)] followed at 3 h by rFVIIa [90 mug/kg intravenous (i.v.)] (n=6), or idraparinux (7.5 mg s.c) followed after 1 week by rFVIIa (90 mug/kg i.v.)(n=6). rFVIIa, given 3 h after idraparinux, significantly reversed the increased thrombin generation time (TGT), the increased activated partial thromboplastin time (aPTT) and prothrombin time (PT), and the reduced prothrombin fragment 1+2 (F1+2) levels caused by idraparinux, although no clear effect of rFVIIa on the endogenous thrombin potential (ETP) was observed. One week after idraparinux, injection of rFVIIa resulted in a similar relative reduction of the remaining increased aPTT, PT and TGT, with correction to pre-idraparinux values. A clear increase of F1+2 was observed, together with a small increase in ETP. We conclude that rFVIIa has significant effects on the idraparinux-inhibited thrombin generation and clotting parameters. These results suggest that rFVIIa may be useful in serious bleeding complications in idraparinux treated patients
AB - We investigated whether the anticoagulant effect of idraparinux, a selective long-acting factor Xa inhibitor, could be neutralized by recombinant factor VIIa (rFVIIa) in healthy male volunteers. We performed a randomized, placebo-controlled trial, comparing idraparinux [7.5 mg subcutaneous (s.c.)] followed at 3 h by rFVIIa [90 mug/kg intravenous (i.v.)] (n=6), or idraparinux (7.5 mg s.c) followed after 1 week by rFVIIa (90 mug/kg i.v.)(n=6). rFVIIa, given 3 h after idraparinux, significantly reversed the increased thrombin generation time (TGT), the increased activated partial thromboplastin time (aPTT) and prothrombin time (PT), and the reduced prothrombin fragment 1+2 (F1+2) levels caused by idraparinux, although no clear effect of rFVIIa on the endogenous thrombin potential (ETP) was observed. One week after idraparinux, injection of rFVIIa resulted in a similar relative reduction of the remaining increased aPTT, PT and TGT, with correction to pre-idraparinux values. A clear increase of F1+2 was observed, together with a small increase in ETP. We conclude that rFVIIa has significant effects on the idraparinux-inhibited thrombin generation and clotting parameters. These results suggest that rFVIIa may be useful in serious bleeding complications in idraparinux treated patients
U2 - https://doi.org/10.1111/j.1365-2141.2003.04811.x
DO - https://doi.org/10.1111/j.1365-2141.2003.04811.x
M3 - Article
C2 - 14871253
SN - 0007-1048
VL - 124
SP - 653
EP - 658
JO - British journal of haematology
JF - British journal of haematology
IS - 5
ER -